On high-speed rotary tablet presses, the ARC-Series Maglev Pump-ARC-2000 Pharma Grade API stream is converted into an immediate-release tablet core by high-shear wet granulation when the raw powder exhibits static angle of repose greater than 45°, Carr compressibility index above 25%, or bulk density below 0.35 g/mL. This route is controlled against USP <711> dissolution testing, USP <905> uniformity of dosage units, USP <1216> friability testing, USP <701> disintegration testing, ICH Q3C residual solvent limits, and ICH Q3D elemental impurity limits. The formulation addition ratio of ARC-2000 Pharma Grade API is held at 2.5–25.0 wt% of the final uncoated core mass; for a 50 mg strength in a 250–280 mg core, the API fraction is typically 18.0–22.0 wt%, while a 200 mg strength with high-density filler may reach 35.0–40.0 wt% only after roller-compacted or granulated densification is confirmed. Binder is hypromellose E5 or povidone K30 at 2.0–5.0 wt%, crospovidone disintegrant at 2.0–4.0 wt%, and sodium starch glycolate at 1.0–2.0 wt%. The granulation is executed in a GEA PMA 150 or equivalent high-shear granulator with impeller speed 250–500 rpm, chopper speed 1500–3000 rpm, and wet massing time 3–8 min; purified water is sprayed to 20–35% w/w of dry powder. End-point is determined by granule size distribution and power consumption, not by fixed time. Wet mass is discharged at LOD 1.5–2.5% after fluid-bed drying with inlet air temperature 55–65 °C and product temperature 32–38 °C. The dried granule is milled through 0.8–1.25 mm screen; oversized material above 1.25 mm is recycled at a rate not exceeding 25% of total granule mass to avoid over-lubrication. Magnesium stearate is added at 0.25–1.0 wt% and blended for 2–5 min at 10–15 rpm. Tableting is performed on a Fette 3090i or Korsch XL 400 at 50,000–120,000 tablets/h with compression force 8–18 kN, main compression dwell time 8–15 ms, and precompression force 2–4 kN. In-process checks are taken every 10–15 min for thickness, hardness 80–120 N, friability below 1.0%, and disintegration below 5 min. Film coating is applied in a pan coater with inlet air 60–70 °C, spray rate 10–20 g/min per kg of tablet load, and weight gain 2.5–4.0%. Terminal finished product types are immediate-release round or oval tablets, aqueous film-coated tablets in HDPE bottles, and blister-pack primary packaging. Published data for ARC-2000 in this exact configuration is limited; therefore the stated ranges are platform parameters derived from industrial solid-dosage manufacturing of poorly soluble APIs and must be confirmed by design-of-experiments at the receiving site.

What Limits Roller Compaction Efficiency When the API Is Moisture-Sensitive and Direct Compression Is Excluded?

For moisture-sensitive batches, aqueous granulation is replaced by dry granulation through roller compaction because contact with water can alter the solid-state form, hydrate the crystal lattice, or depress the glass transition of amorphous fractions. The applicable standards are USP <905>, USP <711>, ICH Q6A for specification setting, 21 CFR 211.166 for stability, and ICH Q3D for elemental impurities. The addition ratio of ARC-2000 Pharma Grade API is 5.0–40.0 wt% of the final filled capsule mass; a 25 mg dose in a 250 mg fill corresponds to 10.0 wt%, and a 100 mg dose in a 300 mg fill corresponds to 33.3 wt%. Excipient loading is microcrystalline cellulose 20–40 wt%, lactose monohydrate 25–55 wt%, crospovidone 2–5 wt%, colloidal silicon dioxide 0.5–1.5 wt%, and magnesium stearate 0.25–1.0 wt%. Roller compaction is executed on a Gerteis Mini-Pactor or Alexanderwerk WP 200 with roll pressure 4–12 kN/cm, roll speed 3–12 rpm, gap 1.5–4.0 mm, and roll surface temperature controlled below 30 °C to prevent sticking. The compact is milled through 0.8–1.25 mm screen; fines below 75 µm are limited to 20–40% of granule mass to avoid powder flow defects and feed-frame segregation on the capsule machine. Capsule filling uses a Bosch GKF 2600 tamping-pin machine at 75,000–150,000 capsules/h; fill weight variation is controlled below 1.5% RSD and sampled at 15-min intervals. Terminal finished product types are hard gelatin capsules and HPMC capsules in blisters or bottles. Published data for ARC-2000 as a roller-compacted API in this specific configuration is limited; granulation response, ribbon density, and content uniformity should be verified against placebo trials and a minimum of three API dose strengths.

Lyophilization Cycle Design and Glass Transition Collapse Control for Injectable Cake

For injectable presentation, ARC-2000 Pharma Grade API is formulated as a sterile lyophilized cake because aqueous solution stability is limited and cold-chain spray-dried powder cannot consistently meet subvisible particulate limits. The manufacturing area follows EU GMP Annex 1, FDA 21 CFR 211.94, 21 CFR 211.167, USP <1>, USP <85>, USP <788>, USP <790>, and ICH Q3D; container closure integrity is tested by vacuum decay per ASTM F2338-09. Bulk solution API concentration is 5.0–50.0 mg/mL, and the final cake mass may contain 5–30 wt% API depending on bulking-agent loading. Mannitol is used at 2–6% w/v, trehalose or sucrose at 1–5% w/v, and phosphate or citrate buffer at 1–10 mM; solution pH is maintained at 5.5–7.5. Compounding is performed in Grade C, sterile filtration through 0.22 µm PES or PVDF membranes is pressure-controlled below 15 psi, and filling is executed in Grade A RABS/isolator at 10–30 vials/min per line. Lyophilization cycle parameters are developed from freeze-drying microscopy and heat-transfer studies: freezing to −45 °C at 0.50–1.00 °C/min, annealing at −20 °C for 2–4 h when mannitol crystallization is required, primary drying at shelf temperature −25 to −10 °C and chamber pressure 50–150 mTorr for 24–72 h, and secondary drying at 30–40 °C for 4–8 h. Residual moisture is maintained below 1.0% by Karl Fischer titration. Terminal finished product types are single-dose vials of lyophilized powder for reconstitution, dual-chamber cartridges, and combination product kits. Because collapse temperature data for ARC-2000 is not publicly disclosed, shelf temperature and chamber pressure windows must be confirmed on the commercial-scale dryer rather than assumed from laboratory vials.

Fluid-bed top-spray granulation is selected when a divided powder or sprinkle presentation is required, or when a fixed-dose combination sachet must be diluted before oral administration. In this configuration, ARC-2000 Pharma Grade API is layered onto sugar spheres or granulated with mannitol at 0.1–15.0 wt% of the finished sachet mass. Binder solution is hypromellose or povidone at 1–3 wt%, taste-masking polymer such as ethylcellulose or amino methacrylate copolymer at 2–5 wt%, sweetener and flavor at 0.5–2.0 wt%, and flow aid at 0.5–1.5 wt%. The relevant standards are USP <711> when the granules are dispersed, USP <905> for unit dose uniformity, ICH Q3C for residual solvents, ICH Q3D for elemental impurities, and 21 CFR 211.110 for in-process control. Fluid-bed processing is performed on a Glatt GPCG 3 or equivalent with inlet air temperature 50–70 °C, product temperature 30–40 °C, atomization air pressure 1.5–2.5 bar, and spray rate 8–20 g/min per kg of substrate. Granules are sieved to 0.5–1.5 mm; product below 0.5 mm is used in sachets only if flow and blend uniformity are confirmed. Sachet filling is executed on horizontal form-fill-seal equipment with seal temperature 120–150 °C, dwell time 0.5–1.5 s, and fill weight precision below 2.0% RSD. Terminal product types include unit-dose sachets for oral suspension, sprinkle granules for co-administration with soft food, and hospital unit-dose cups.

If Terminal Sterilization Is Required, the Solution Formulation Must Tolerate Moist-Heat Load and Primary Packaging Extractables

A ready-to-use solution route is selected when the clinical setting requires immediate administration without reconstitution, or when a prefilled syringe presentation is specified. ARC-2000 Pharma Grade API is dissolved at 0.5–20.0 mg/mL, buffered with phosphate or citrate at 10–20 mM, adjusted for tonicity with sodium chloride 0.9% w/v or mannitol 4–5% w/v, and maintained at pH 6.0–7.4. The process follows 21 CFR 211.113, USP <1>, USP <788>, USP <790>, ISO 7886-1 for syringes, and ICH Q3D. Compounding is completed in Grade C, sterile filtration through 0.22 µm membranes is performed immediately before filling, and the solution is filled into pre-sterilized syringes or vials. Terminal sterilization is conducted at 121 °C for 15 min or 115 °C for 30 min; the lower-temperature cycle is permitted only when the drug substance shows measurable degradation above 115 °C. Headspace oxygen is reduced to 2–5% residual by nitrogen purging. Container closure integrity is verified by vacuum decay per ASTM F2338-09. Terminal finished product types are prefilled syringes, single-dose vials, and IV bags. Published data for ARC-2000 in this specific configuration is limited; solution-state forced degradation studies and extractables data from the selected primary packaging must be generated before release of the terminal sterilization cycle.